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CYSTEINE DELETED TACHYPLESIN 
 PEPTIDE ANALOGS AS 
  ANTI-CANCER AGENTS
Jaylen E. Taylor  
Dr. Deborah Heyl-Clegg, Mentor
ABSTRACT
 Adenocarcinoma is a common type of non-small cell 
cancer that represents 80% of all diagnosed lung cancers. Typi-
cal treatment methods include surgery, radiation therapy, and 
chemotherapy, or some combination of the three. Although radia-
tion therapy and chemotherapy treatments are effective at killing 
cancer cells, the side effects and symptoms associated with these 
treatments can cause severe damage to the patient’s body and even 
encourage some fatal illnesses, such as sepsis. Research has been 
focused on the development of other methods of treatment that 
would be less harmful or even non-harmful to patients. Antimicro-
bial peptides are known for their potential in modern antibiotics 
to treat bacteria-caused illnesses. The antimicrobial peptide, cys-
teine deleted tachyplesin (CDT), demonstrates both antibacterial 
as well as anticancer properties. To improve the development of 
CDT into a possible treatment for adenocarcinoma of the lung, 
analogs of the peptide CDT containing the hyaluronan binding 
sequence are being synthesized and tested on the cell line A549, 
with the hopes of improving their anticancer characteristics and to 
understand better the mechanism that allows CDT and its analogs 
to cause adenocarcinoma cell death.
INTRODUCTION
Adenocarcinoma
 In 2016, the American Cancer Society issued a report 
indicating that 526,510 men and women were living with lung 
cancer, and a projected 224,390 additional people would be di-
agnosed before the end of that year. A year later, the 2017 report 
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showed that lung cancer had become the second most diagnosed 
type of cancer in the United States in both men and women. The 
report estimated that 222,500 cases would be diagnosed before the 
conclusion of 2017, and, of those patients, an estimated 155,870 
would die due to complications from the illness (American Cancer 
Society, 2017).
 Adenocarcinoma of the lung is the most commonly diag-
nosed type of non-small cell lung cancer (American Thoracic Soci-
ety 2014). Lung cancer can be divided into two sub-categories: small 
cell cancer and non-small cell cancer. Adenocarcinoma of the lung is 
a type of non-small cell cancer. The cancer forms in the outer tissues 
of the lung from cells that are responsible for making mucus (The 
Roche Group 2017). Most lung cancers are known to be asymptom-
atic until the late stages (III and IV; Miller et al. 2016). Adenocar-
cinoma of the lung is characterized as being a slow growing cancer, 
however, with the usual diagnosis of the cancer being in stage IV at a 
median age of 70 years old, recovery can be very difficult, even with 
aggressive treatment (American Cancer Society 2016).
 Lung cancer, specifically adenocarcinoma, is directly 
linked to levels of environmental carcinogenic exposure (Ameri-
can Cancer Society 2017). Men and women who smoke are 25 
times more likely to develop lung cancer (American Cancer So-
ciety 2017). Risk factors include smoking and exposure to radon 
gas, asbestos, diesel exhaust, radiation, and air pollution (Ameri-
can Cancer Society 2017). In a Croatian study conducted in 2014 
by Kukulj et al., the lung cancer treatments of 212 newly diag-
nosed patients were monitored. Of the 212 patients, 186 were 
diagnosed with small cell lung cancer, and 89 of these patients 
had adenocarcinoma of the lung. As per the trend reported by the 
American Cancer Society, the study found that median age of di-
agnosis was 65 years old, and 157 of the 212 patients (74.1%) 
had stage IV cancer. Of the patients who took part in the study, 
182 were smokers (85.5%). The data on the patients involved in 
this cohort study solidify the link between carcinogenic exposure, 
such as long-term smoking habits, and adenocarcinoma of the 
lung (Kukulj et al. 2014).
 In a separate study conducted by Yang et al. from 1986 to 
1998, approximately 38,000 women between the ages of 55 and 
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69, living in Iowa, were monitored with the intent of linking the 
risk factor of smoking to the development of lung cancer. This 
research study followed the women for 13 years. Of the 38,006 
women in this study, 34% were former or current smokers at the 
beginning of the study. Of the entire cohort, 234 of the women 
developed adenocarcinoma of the lung. Published in 2002, this 
study also draws a very strong conclusion that smoking, current 
or past, can increase the risk of developing adenocarcinoma of the 
lung (Yang et al. 2002).
 The treatment for adenocarcinoma is usually surgery, in 
combination with chemotherapy (American Cancer Society 2017). 
An efficient and safe treatment method that would both eradicate 
the cancer and not harm the patient is highly sought after.
 The Dangers of Chemotherapy
Chemotherapy is a well-known cancer treatment method. It is 
known to be efficient in killing cancerous cells; however, this 
treatment method is also very effective at killing the healthy tissue 
and cells surrounding the cancer. According to the American Tho-
racic Society (2014), after a non-small cell lung cancer progress-
es to stage III, chemotherapy is a strongly considered treatment 
method. Chemotherapy causes side effects that are degenerative 
to the quality of life of the patient, including, but not limited to, 
fatigue, hair loss, nausea and vomiting, anemia, increased risk of 
infection, kidney damage, and nerve damage (American Thoracic 
Society 2014). The most concerning risk from chemotherapy is 
the possibility of infection, which could prove deadly. Chemo-
therapy kills the cancer cells in the body that grow quickly, but it 
also kills the cells that naturally grow quickly, such as hair cells, 
nail cells, and white blood cells (Centers for Disease Control and 
Prevention [CDC] 2017). With low white blood cell counts, a 
patient undergoing chemotherapy is susceptible to infection and 
even sepsis (CDC 2017). The efficiency, effectiveness, and safety 
of chemotherapy call into question whether chemotherapy should 
remain one of the primary treatment methods for distinct types of 
lung cancer, including adenocarcinoma. There has been explora-
tion into other treatment methods, such as targeted therapy. The 
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possibility of using antimicrobial peptides (AMPs) as a safe, ef-
ficient treatment specifically for adenocarcinoma would bring us 
one step closer to understanding the cure for this type of cancer.
Antimicrobial Peptides
 AMPs are found in plants, animals, and other organisms. 
AMPs are characterized as both cationic and amphipathic (Sch-
weizer 2009). Recent advances in research have encouraged the 
use of AMPs as targeted therapy to combat especially resistant 
bacterial strains. The success of these targeted therapies is con-
sistent with interaction with the cell membrane. Antimicrobial 
peptides that kill bacteria through membrane interaction alone are 
more likely to kill bacteria without giving them a chance to be-
come resistant (Riedl et al. 2011). To do this, the membrane of 
the bacterial cell must be penetrated. Models summarizing how 
activity may take place are based both on the known character-
istics of the bacterial cell and the peptide. The significant differ-
Figure 1. Visual comparison of the components of the cell membrane of a healthy 
mammalian cell and a bacterial cell. Antimicrobial peptides have more interaction 
with the negative bacterial cell membranes due to charge. The healthy mammalian cell 
membrane is neutral (Riedl et al. 2011).
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ence between the bacterial cells and the healthy mammalian cells 
is found in the charge of the membrane. Both gram-positive and 
gram-negative bacteria have an overall negatively charged mem-
brane. Bacteria gain their charge due to the molecules found on 
the outside of the membrane. Bacterial cells are anionic due to 
the acidic phospholipids found on the membrane. Healthy mam-
malian cells, on the other hand, are overall neutral, due to the pres-
ence of both cationic and anionic phospholipids, giving them a 
zwitterionic character. Figure 1 (above) shows the composition of 
the membrane of the cancer cell and bacterial cell comparatively 
(Riedl et al. 2011). Because of the similarity, the mechanism by 
which the membrane disruption takes place and induces cell death 
is also thought to be similar.
Potential Mechanisms
 There are four commonly cited models that seek to sum-
marize the permeation of the bacterial or cancer cell membrane. 
One of the possible mechanisms of the antibacterial characteristic 
of AMPs is the invasion of the bacterial membrane after contact 
is made, causing cell lysis and eventually cell death. Proposed 
mechanisms for the interaction that cause cell lysis are the barrel-
stave model, the toroidal model (also known as worm-hole), and 
the carpet model. All are visually represented in Figure 2 (Giuliani 
et al. 2008). The product of all the models is the creation of a pore 
in the plasma membrane in the case of bacteria, or the cell mem-
brane in the case of a mammalian cancer cell. In the barrel-stave 
model, the peptide selectively attaches to the membrane due to 
the attractive charges of the peptide (positive) and the membrane 
(negative). Multiple molecules of the peptide group together to 
create a channel, lined with peptide, within the membrane. The 
hydrophobic region of the peptide faces out, towards the hydro-
phobic regions of the lipid bilayer (Brogden 2005). Similarly, in 
the toroidal model, the peptide creates a pore, but the lipid bi-
layer curves around so that the hydrophilic heads are facing out 
where the lipid bilayer meets the hydrophobic side of the peptide 
(Brogden 2005). In the carpet model, the peptide forms a layer 
over the membrane and breaks the membrane down, causing cell 
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lysis (Brogden 2005). This is sometimes also referred to as the 
"detergent model" because the peptide breaks downs the mem-
brane like a detergent.
Tachyplesin-1
Tachyplesin-1 (TP-1) is a β-hairpin cationic antimicrobial peptide 
isolated from the hemocyte debris of the Japanese horseshoe crab, 
Tachypleus tridentatus (Nakamura et al. 1988). TP-1’s unaltered 
sequence is 17 amino acids in length (see Figure 3; Nakamura 
et al. 1988). Using the single character symbol for each amino 
acid, the sequence is as follows: KWCRFRVCGICYRRCR. The 
peptide has been found to exhibit antimicrobial properties. The 
increasing resistance of bacterial strains to antibiotics has caused 
an interest in antimicrobial peptides, such as TP-1, as a solution 
(Edwards et al. 2017).
 TP-1 exhibits membrane disruptive activity in both gram-
negative and gram-positive bacteria as well as fungi (Edwards et 
Figure 2. Three potential mechanisms for the interaction of antimicrobial peptides and 
the cell membrane of bacteria cells or cancer cells. The diagram also depicts how the 
peptide interacts considering the polarity of the peptide (Giuliani et al. 2008)
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al. 2017). Previous studies have shown that TP-1 caused rapid cell 
death to E. coli and S. aureus. In a study conducted by Hong et 
al. (2015), E. coli treated for 60 minutes with the peptide had a 
survival rate of 27%, while S. aureus being treated for 30 minutes 
had a 10% survival rate. The antimicrobial properties of TP-1 are 
substantiated by its efficiency in killing bacterial strains, but how 
exactly does this take place? In the same study, the peptide was 
dyed with fluorescein isothiocyanate (FITC) and visualized with 
laser confocal scanning microscopy to determine the process of 
TP-1. Hong et al. (2015) wrote the following summarizing the 
process of TP-1 causing cell death in E. coli and S. aureus:
 FITC-labeled tachyplesin I (10 μg/mL) pene-
trated the cell membrane and accumulated in the cyto-
plasm immediately after being added to the E. coli and 
S. aureus cell cultures. In E. coli, tachyplesin I later ac-
cumulated at the head of the cytoplasm and caused cell 
body transformation and also accumulated at a hole in 
the cytoplasm. In S. aureus, no cell membrane disrup-
tion was observed following treatment with 10 μg/mL of 
tachyplesin I, the same phenomenon was also observed 
following treatment with 20 g/mL of tachyplesin I . The 
mode of action of tachyplesin I on E. coli was determined
to be dose-dependent. Membrane disruption was clearly 
visible in E. coli after treatment with 20 g/mL of tachyplesin 
I for 3 min and 40 g/mL in no time. These results indicate 
that the primary target of tachyplesin I is the cell mem-
brane and cytoplasm of E. coli and S. aureus and that it has 
a different killing mechanism for each bacterium. (p. 71)
 To determine which amino acid(s) were responsible for 
the activity, analogs of the sequence were tested in a separate 
study (Edwards et al. 2017). In each analog, each amino acid was 
replaced with alanine, one at a time, and additional analogs were 
made where a cysteine was replaced with alanine. The experiment 
tested a total of 32 analogs. All of the peptide analogs, despite 
their rearrangement, retained their cationic charge. By altering and 
rearranging the sequence of some analogs, Edwards et al. (2017) 
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found that they were able to increase and decrease the activity of the 
peptide analogs relative to TP-1. The analogs with the highest ef-
ficiencies were tested for toxicity against human embryonic kidney 
cells (HEK293) and human red blood cells (RBCs). Determining if 
these analogs were harmful to healthy cells⎯causing cell lysis⎯is 
a crucial step in determining whether the peptide could even be con-
sidered an option for human treatment methods. The experiment 
found that, while the antimicrobial activity was efficient, the hemo-
lytic activity was often too high to be considered a viable treatment 
for humans, whereas when the concentration was decreased, there 
was little to no activity (Edwards et al. 2017).
 As anticancer agents, peptides with anticancer activity 
also initially rely on membrane interactions to induce apoptosis 
(Chen et al. 2001). Chen et al. (2001) studied the effects of RGD-
Tachyplesin, where amino acids are added at the N-terminus, on 
TSU prostate cancer cells. They found that the disruption of the 
mitochondria causes the activation of an apoptotic cascade. Over-
all, this study demonstrated the ability of RGD-Tachyplesin to 
inhibit tumor growth and damage the cell membranes of cancer 
cells to induce apoptosis. To explore further the abilities of TP-1, 
previous studies have focused on the effects on the cell cycle. A 
study conducted by Li et al. (2003) analyzed the effects of TP-1 
on the regulation of the cell cycle in human heptocarcinoma cells 
(SMMC-7721). Their experiment demonstrated that TP-1 can ar-
rest cells at the G0/G1 phase. P53 and p16 protein levels were 
also found to be significantly lower in the heptocarcinoma cells 
that had been treated with TP-1. The proteins p53 and p16 both 
interact with tumor suppressor pathways (Beauséjour et al. 2003). 
When these proteins are mutated, the affected cells are more sus-
ceptible to becoming cancerous (Figure 3).
Cysteine Deleted Tachyplesin (CDT)
 Cysteine deleted tachyplesin (CDT) is the analog of TP-1 
with the four cysteines completely removed from the sequence. In 
doing this, the peptide is still β-hairpin in shape despite elimina-
tion of the disulfide bonds (Ramamoorthy et al. 2006). CDT is 13 
amino acids in length with the following sequence: KWFRVYR-
GIYRRR. The activity of CDT was studied by Saravanan et al. 
(2012), and the study concluded that the bacterial activity, like 
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TP-1, is due to the selectivity for the negatively charged lipids. 
CDT successfully neutralized the LPS and “disrupted the perme-
ability barrier of the outer membrane” (Saravanan et al. 2012 p. 
1613). CDT succeeds in other areas of efficiency where TP-1 was 
lacking as well. By running a hemolysis assay comparing TP-1 
and CDT, it was concluded that CDT did not cause cell lysis in 
concentrations less than 200 μg/mL, while TP-1 caused 10% of 
hemolysis at concentrations of 100 μg/mL and 25% at concentra-
tions of 150 μg/mL (Ramamoorthy et al. 2006). This makes CDT 
much more promising as a pharmaceutical, due to the improved 
therapeutic index.
 As an anticancer agent, CDT was found to interact with 
heparan sulfate and chondroitin sulfate, anionic glycosaminogyl-
cans found on the surface of the cancer cell membrane (Fadnes et
al. 2009). Fadnes et al. (2009) found that lymphoma cells were 
less vulnerable to other cationic peptides (lactoferricin) if they ex-
pressed heparin sulfate on the cell surface. Their study concluded 
that, although some negatively charged molecules help with se-
lectivity, molecular components such as heparan sulfate and chon-
droitin sulfate on the membrane of a cancer cell can inhibit pep-
tide activity as well (Fadnes et al. 2009).
Figure 3. Tachyplesin-1 amino acid sequence depicting β-hairpin structure  
(Edwards et al. 2017).
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 Wood et al. (2014) conducted a study of CDT and its ana-
logs that analyzed the hemolytic activity as well as the antimicro-
bial effects of CDT with the removal of arginine residues from the 
C-terminus, to determine how many were necessary for activity. 
As arginine was systematically removed from the C-terminus, the 
activity against E. coli and S. aureus increased, but only CDT-
desRR resulted in virtually no hemolysis. The removal of a third 
arginine residue caused a significant increase in hemolysis and a 
decrease in antimicrobial activity. CDT required 67 μM to cause 
less than 1% hemolysis where CDTdesRR required 650 mM to 
have the same hemolytic effect (Figure 4). These findings are im-
portant because they qualify CDT as a possible therapeutic treat-
ment for cancer; the hemolysis must be practically non-existent to 
be considered safe. If CDT and its analogs had resulted in elevated 
levels of hemolysis, then they would be dangerous and potentially 
deadly to humans.
 Evans et al. (2017) tested four separate peptides against 
adenocarcinoma human alveolar basal epithelial cell line (A549), 
E. coli and S. aureus; CDT, D-CDT (where all amino acids have 
the D-configuration), reverse CDT (where the amino acid se-
quence was “backwards” relative to CDT), and reverse D-CDT. 
Their findings showed that D-CDT was more selective for the 
negatively charged cells than the other peptide analogs. In ad-
dition, D-CDT was also showed the most activity with the least 
amount of hemolytic activity. D-CDT had an IC50 of 9.813 μM 
against A549 lung cancer cells, the most efficient of the analog 
they tested. D-CDT’s ability to exhibit cytotoxicity against the ad-
Figure 4. Molecular structure of CDT (pepbank.mgh.harvard.edu)
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enocarcinoma cells substantiates its classification as a peptide that 
shows activity against microbial and cancer cells, but lacks activ-
ity against healthy mammalian cells.
The Hyaluronan Binding Sequence and Cancer
Hyaluronan (HA) was discovered in 1934 by Karl Meyer 
and John Palmer. One member of a bigger system of molecules, 
receptors, and synthases that allow cancer cells to interact with the 
environment around them (Simoni et al. 2002), HA is a glycos-
aminoglycan made up of repeating units of D-glucuronic acid and 
N-acetylglucosamine (see Figure 5 below; Necas et al. 2008). To
survive, cancer cells must have the ability to adhere to the matrix
(Delpech et al. 1997). Tumor cells contain HA, which induces cell
growth, migration, and the ability to metastasize (Misra et al. 2015).
HA is produced by enzymes called hyaluronan synthases and is de-
graded by enzymes called hyaluronidases (Kultii et al. 2012).
HA protects tumors from attacks from the immune system 
(Misra et al. 2015). Focusing on the mechanism and cell receptors 
that aid the relationship between HA and tumor growth could be the 
key to defining new treatment methods for cancer. By disrupting 
the protective environment of the tumor cell, the effectiveness of 
the anti-cancer properties of the CDT may be enhanced. Evans et 
al. (2017) tested and compared the efficiency of CDT analogues in 
the presence of hyaluronidase, which degrades HA and chondroi-
tin sulfate. As discussed above, chondroitin sulfate inhibits cationic 
peptide activity (Fadnes et al. 2009). D-CDT lost its activity when 
Figure 5. The chemical structure of Hyaluronan (Necas et al. 2008).
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the cells were treated with hyaluronidase before the peptide, sug-
gesting that HA somehow plays a role in the anti-cancer mechanism 
of D-CDT. In all, the study ruled out apoptosis as a mechanism, un-
like RGD-Tachyplesin used, but retained the dependence on the HA 
interaction as a possibility (Evans et al. 2017).
The CD44 receptor is characterized by its interaction 
with HA, along with other receptors such as LYVE-1, TLR-4, and 
RHAMM (Matthaiolampakis et al. 2015; Litwinuik et al. 2016; 
see Figure 6 below). The binding sequence B(X7)B is the HA 
binding sequence, which allows peptides to interact with receptor 
domains (Yang et al. 1994). B represents a basic amino acid, argi-
nine or lysine, and X7 represents any other amino acid (Yang et al. 
1994.). This binding sequence can be found within the sequence of 
CDT (RVYRGIYRR). This is similar to the sequence that Wood et 
al. (2014) found to be effective against bacteria but did not induce 
hemolysis. The mechanism to kill cancer cells could therefore be 
increased, due to the binding sequence of HA found in CDT inter-
acting with receptors found on the membrane of the cancer cell.
Looking forward, testing the shorted internal part of CDT, 
which only contains this binding sequence, against cancer cells in 
both the natural L-form and D-form may exhibit increased activity 
against A549 lung cancer cells. Shortening the sequence of the pep-
Figure 6. Receptors that interact with Hyaluronan (Litwinuik et al. 2016.)
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tide makes it more deliverable, less immunogenic, and both easier 
and cheaper to synthesize. The D-form affords some protection from 
natural proteases, which only recognize L-amino acids, and gives it a 
longer half-life in addition to unique conformational properties.
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